CLINICAL_TRIALS ClinicalTrials.gov record update

PD-1 Immune Checkpoint Inhibitor Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma (T2-3N0 or T1-2N1 and EBV-DNA≤4000 Copy/ml),A Single-arm, Phase II Clinical Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05229315
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:13.647796+00:00
Published At: 2023-04-13T00:00:00+00:00
Record Updated At: 2023-04-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Nasopharyngeal Carcinoma", "T2-3N0 or T1-2N1", "EBV-DNA\u22644000 Copy/ml"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-04-13"
protocolSection.identificationModule.nctId: "NCT05229315"
protocolSection.identificationModule.officialTitle: "PD-1 Immune Checkpoint Inhibitor Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma (T2-3N0 or T1-2N1 and EBV-DNA\u22644000 Copy/ml),A Single-arm, Phase II Clinical Trial"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.